Shire, AB Biosciences in Autoimmune Disease Pact
Shire and AB Biosciences, a Boston, Massachusetts-based biotechnology company, have signed a pact granting Shire an exclusive license to develop and commercialize AB Biosciences’ pan receptor interacting molecule (PRIM) program, which uses AB Biosciences’ proprietary oligomeric Fc technology platform.
Shire says PRIM, a recombinant immunoglobulin product candidate, has shown enhanced biological activity in preclinical models of autoimmune and inflammatory diseases.
Under the agreement, AB Biosciences will grant Shire an exclusive, worldwide license to its intellectual property relating to its PRIM program. AB Biosciences will receive an upfront license fee payment from Shire and is eligible to receive contingent research, development, and commercialization milestone payments as well as royalty payments. No further terms of the agreement were disclosed.